O3-S6.02 Screening forMycoplasma genitalium,Chlamydia trachomatisandBacterial vaginosisin a public hospital, pregnancy termination service

Abstract

participant demographic or behavioural characteristics between arms. Adherence to study medication did not differ between arms: 382 (91%) took all or most oral metronidazole and 330 (80%) all or most vaginal therapy. Retention rates were high, with 77 (17%) lost to follow-up over 6 months, and did not differ between arms. Participants contributed 153.7 person years of follow-up to analyses. On exit survey 88% of participants did not know or correctly guess the vaginal therapy they had received. Six month cumulative BV recurrence rates did not differ between study arms by per protocol analysis: MetPlac (32%, 95% CI 24% to 41%) MetProb (33%, 25% to 42%) and MetClin (34%, 26% to 42%), p>0.05 (Abstract O3-S5.06 figure 1 Abstract O3-S5.06 Figure 1 Conclusions The addition of vaginal clindamycin or a vaginal probiotic to oral metronidazole does not improve 6 month BV recurrence rates. This is the first RCT to evaluate the efficacy of combination clindamycin/metronidazole for BV treatment, and has important implications for clinical practice. Combination therapy is often used in patients with recurrent BV, but evidence to support this practice has not been available.

Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne

“…6 A surveillance study at the Royal Women’s Hospital Melbourne (2011) of 1627 women undergoing surgical termination of pregnancy (mean age 26.4 years) found the prevalence of Mg to be 4.6% and the prevalence of Ct 5.3% in this population. 7 A study in the United Kingdom found 4.5% of asymptomatic female and male patients attending a sexual health clinic over a six-month period to be positive for Mg . 8 Both these studies highlight the potential value of testing for Mg in asymptomatic people at risk of STI.…”